Combination Therapy of Bcl-2/X L dual Inhibitor AZD0466 with Acalabrutinib to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma

被引：1

作者：

Li, Yijing ^{[1
]}

Liu, Yang ^{[1
]}

Che, Yuxuan ^{[1
]}

McIntosh, Joseph ^{[1
]}

Jordan, Alexa A. ^{[1
]}

Leeming, Angela ^{[1
]}

Andersen, Courtney L. ^{[2
]}

Cidado, Justin ^{[2
]}

Jin, Jingling ^{[1
]}

Jiang, Vivian Changying ^{[1
]}

Wang, Michael ^{[1
,3
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[2] AstraZeneca, Oncol R&D, Waltham, MA USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-151609

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1867

引用

页码：1867 / +

页数：4

共 36 条

[21] A Phase 1 trial of the pan bcl-2 family inhibitor obatoclax mesylate (GX15070) in combination with bortezomib in patients with relapsed/refractory mantle cell lymphoma
Goy, Andre
Ford, Peggy
Feldman, Tatyane
Pecora, Andrew
Goldberg, Stuart
Donato, Michele
Siegel, David
Panush, David
Berger, Mark S.
BLOOD, 2007, 110 (11) : 757A - 757A
[22] CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma (DLBCL).
Wilson, KS
Sehn, LH
Berry, B
Chhanabhai, M
Connors, JM
Fitzgerald, CA
Gill, KK
Klasa, R
Skinnider, B
Gascoyne, RD
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 564S - 564S
[23] A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hillmen, Peter
Qamoos, Hope
Uyei, Anne
Rothbaum, Wayne M.
Jurczak, Wojciech
Thieblemont, Catherine
Byrd, John C.
BLOOD, 2020, 136
[24] Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib
Tam, Constantine S.
Verner, Emma
Lasica, Masa
Arbelaez, Alejandro
Browett, Peter J.
Soumerai, Jacob D.
Hilger, James
Fang, Yiqian
Huang, Jane
Simpson, David
Opat, Stephen
Cheah, Chan Yoon Y.
BLOOD, 2021, 138
[25] PRELIMINARY SAFETY AND EFFICACY DATA FROM PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES TREATED WITH THE NOVEL B-CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB-11417 IN MONOTHERAPY OR IN COMBINATION WITH ZANUBRUTINIB
Ghia, P.
Tam, C.
Verner, E.
Lasica, M.
Arbelaez, A.
Browett, P.
Soumerai, J.
Hilger, J.
Fang, Y.
Huang, J.
Simpson, D.
Opat, S.
Cheah, C.
HAEMATOLOGICA, 2022, 107 : 33 - 34
[26] Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)
Nastoupil, Loretta J.
Andersen, Clark R.
Ayers, Amy
Wang, Yucai
Habermann, Thomas M.
Chihara, Dai
Kahl, Brad S.
Link, Brian K.
Cohen, Jonathon B.
Martin, Peter
Lossos, Izidore S.
Casulo, Carla
Lin, Ruitao
Li, Ziyi
Larson, Melissa C.
Maurer, Matthew J.
Huynh, Lynn
Gao, Chi
Ramasubramanian, Ramya
Sheng, Mei
Mutebi, Alex
Wang, Tongsheng
Jun, Monika
Wang, Anthony
Kamalakar, Rajesh
Kalsekar, Anupama
Cerhan, James R.
Flowers, Christopher R.
BLOOD, 2023, 142
[27] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL): Results from Phase 2 of ZUMA-2
Wang, Michael
Munoz, Javier
Goy, Andre
Locke, Frederick
Jacobson, Caron
Hill, Brian
Timmerman, John
Holmes, Houston
Jaglowski, Samantha
Flinn, Ian
McSweeney, Peter
Miklos, David
Pagel, John
Kersten, Marie Jose
Peng, Weimin
Zheng, Lianqing
Rossi, John
Jain, Rajul
Rao, Arati
Reagan, Patrick
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 41 - 43
[28] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study
Wang, Michael L.
Munoz, Javier
Goy, Andre
Locke, Frederick L.
Jacobson, Caron A.
Hill, Brian T.
Timmerman, John M.
Holmes, Houston
Jaglowski, Samantha
Flinn, Ian W.
McSweeney, Peter A.
Miklos, David B.
Pagel, John M.
Kersten, Marie Jose
Peng, Weimin
Zheng, Lianqing
Rossi, John M.
Jain, Rajul K.
Rao, Arati V.
Reagan, Patrick M.
BLOOD, 2019, 134
[29] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study
Wang, Michael
Munoz, Javier
Goy, Andre
Locke, Frederick L.
Jacobson, Caron A.
Hill, Brian T.
Timmerman, John M.
Holmes, Houston
Jaglowski, Samantha
Flinn, Ian W.
McSweeney, Peter A.
Miklos, David B.
Pagel, John M.
Kersten, Marie Jose
Peng, Weimin
Zheng, Lianqing
Rossi, John M.
Jain, Rajul K.
Rao, Arati V.
Reagan, Patrick M.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S1 - S1
[30] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results from Phase 2 of ZUMA-2
Wang, Michael
Munoz, Javier
Goy, Andre
Locke, Frederick L.
Jacobson, Caron A.
Hill, Brian T.
Timmerman, John M.
Holmes, Houston
Jaglowski, Samantha
Flinn, Ian W.
McSweeney, Peter A.
Miklos, David B.
Pagel, John M.
Kersten, Marie Jose
Peng, Weimin
Zheng, Lianqing
Rossi, John M.
Jain, Rajul K.
Rao, Arati V.
Reagan, Patrick M.
MOLECULAR THERAPY, 2020, 28 (04) : 573 - 573

← 1 2 3 4 →